|
Registration benefits include:
|
|
Access to CME/CE programs and certification
|
|
|
Free subscription to Biologic Bulletin newsletter
|
|
|
Reminders of new CME/CE activities
|
 REGISTER NOW
|
|
|
|
|
|
 |
| CME/CE Programs : Managing the Psoriasis Patient With Concomitant Disease |
Release date: October 2009
Expiration date: October 31, 2010
Estimated time to complete activity: 30 minutes
Co-provided by Curatio CME Institute and The Dermatology Nurses’ Association
Support for this activity has been provided through educational grants from Amgen and Wyeth Pharmaceuticals and Centocor Ortho Biotech.
Activity Overview
A 62-year-old male patient presents to your virtual office with severe psoriasis. Among the issues that you need to consider are this patient’s previous history of renal cell carcinoma, active hepatitis C, and alcoholism. You—in consultation with Jeffrey Crowley, MD and Melodie Young, MSN, RN, A/GNP-C—are managing his care. "Consult" with Dr. Crowley and your colleagues as you consider treatment options for this complex case. This activity follows the progression of the case, solicits your clinical input on key aspects of treatment, and presents recommendations provided by other clinicians that have "consulted" on this case.
Target Audience
This activity has been designed to meet the educational needs of dermatologists, dermatology residents and fellows, dermatology nurses, nurse practitioners, physician assistants, and other health care professionals involved in the care of patients with moderate to severe psoriasis.
Learning Objectives
Upon completion of this activity, participants should be able to: - Assess the efficacy, long-term safety, and recommended monitoring associated with traditional and biologic systemic agents for the treatment of moderate to severe psoriasis
- Develop treatment strategies for difficult-to-manage cases of psoriasis, including combination systemic therapy, transitioning to biologic agents, and transitioning between biologic agents
- Evaluate risks, benefits, and contraindications for medications to treat moderate to severe psoriasis, taking into consideration complex patient characteristics such as concomitant disease
Faculty
Jeffrey J. Crowley, MD
Bakersfield Dermatology and Skin Cancer Medical Group
Bakersfield, California
Assistant Clinical Professor
Department of Medicine
University of California
Los Angeles, California
Melodie Young, MSN, RN, A/GNP-C
Nurse Practitioner
Modern Dermatology, a Baylor-Health Texas Affiliate
Adjunct Clinical Instructor
The University of Texas Arlington, Graduate School of Nursing
Dallas, Texas
Accreditation and Credit Designation Statements
Physician
Curatio CME Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Curatio CME Institute designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nursing
Dermatology Nurses' Association (DNA) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's COA.
Provider approved by the California Board of Registered Nursing, Provider Number CEP5708.
Accreditation refers to educational content only.
Method of Participation
There are no fees for participating in this CME/CE activity. To receive credit during the period October 2009 to October 31, 2010, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the activity evaluation form.
Media
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
Disclosure
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Jeffrey J. Crowley, MD, has disclosed the following relevant financial relationships:
| Consultant | Abbott, Centocor Ortho Biotech, Genentech | | Investigator | Abbott, Amgen, Genentech | | Speaker | Abbott, Genentech |
Melodie Young, MSN, RN, A/GNP-C, has disclosed the following relevant financial relationships:
| Advisor | Abbott, Centocor Ortho Biotech | | Speaker | Abbott, Amgen, Astellas, Centocor Ortho Biotech |
Curatio CME Institute
Shari J. Dermer, PhD, Medical Director, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
Derek Warnick, CME Director, has disclosed no relevant financial relationships.
Disclaimer
The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, the Dermatology Nurses' Association, Amgen and Wyeth Pharmaceuticals, and Centocor Ortho Biotech do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, the Dermatology Nurses' Association, Amgen and Wyeth Pharmaceuticals, or Centocor Ortho Biotech. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
| Generic Name | Trade Name | Approved Use (if any) | Unapproved/Investigational Use | | Etanercept | Enbrel | Treatment of adult patients (18 years or older) with chronic to moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy | Treatment of hepatitis C | | Infliximab | Remicade | Treatment of adult patients with chronic severe (ie, extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate | Treatment of hepatitis C |
Hardware/Software Requirements - Version 5.0 or higher for Microsoft Internet Explorer or Netscape 6 or higher
- If you are using a Mac computer system and are experiencing problems with your browser, we suggest downloading the latest version of Firefox for Mac
- Adobe Flash Player plugin v.8.0+
Contact Information
PsoriasisTx
100 Campbell Boulevard
Suite 103
Exton, PA 19341
editor@psoriasistx.com
Policy on Privacy and Confidentiality
Curatio CME Institute makes every effort to protect the privacy of PsoriasisTx.com users; user information is used only to maintain records as required by the American Medical Association (AMA) and the ACCME.
Curatio CME Institute does not require individuals to register to use PsoriasisTx.com; registration is only required for physicians, health care professionals, and other users to participate in and receive CME/CE credit for accredited educational programs hosted on PsoriasisTx.com
Curatio CME Institute is required by the AMA and the ACCME (and occasionally by other accrediting organizations) to collect user information that will allow Curatio CME Institute to issue a CME/CE certificate. Curatio CME Institute is required to keep this information on file for up to 6 years. The information is stored in a secure database and used only to verify individual participation in a CME/CE activity and to reissue a certificate if a user’s original certificate is lost or misplaced.
Information gathered through PsoriasisTx.com will not be released to any other company or organization for any purpose; this information remains confidential. At the end of the mandatory 6-year period, these records will be destroyed.
Curatio CME Institute uses Web site tracking software to determine how PsoriasisTx.com is used. This information helps Curatio determine the best strategies for improving PsoriasisTx.com and better meeting the needs of its users. This software does not identify individual users.
PsoriasisTx.com does not employ cookies or any other software that violates a user's privacy.
If you have any questions about PsoriasisTx.com or any Curatio CME Institute policies, you may contact us at editor@psoriasistx.com.
Thank you for using PsoriasisTx.com.
|
|
|
|
